5-Dec-2025
UNCY Faces Federal Securities Fraud Class Action Allegations Over FDA Compliance Disclosures
Market Chameleon (Thu, 4-Dec 6:36 AM ET)
Globe Newswire (Wed, 3-Dec 9:13 AM ET)
Globe Newswire (Tue, 2-Dec 12:39 PM ET)
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Globe Newswire (Tue, 25-Nov 7:05 AM ET)
UNCY Faces Shareholder Scrutiny Over FDA Compliance—What’s Behind the Investigation?
Market Chameleon (Fri, 14-Nov 6:46 AM ET)
Globe Newswire (Fri, 14-Nov 9:26 AM ET)
Globe Newswire (Thu, 13-Nov 5:40 PM ET)
OLC Pill Burden Data and Cash Runway Strengthen Unicycive’s Path Toward NDA Resubmission
Market Chameleon (Wed, 12-Nov 6:59 AM ET)
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Wed, 12-Nov 7:05 AM ET)
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Unicycive Therapeutics trades on the NASDAQ stock market under the symbol UNCY.
As of December 5, 2025, UNCY stock price declined to $6.23 with 405,910 million shares trading.
UNCY has a beta of 1.86, meaning it tends to be more sensitive to market movements. UNCY has a correlation of 0.14 to the broad based SPY ETF.
UNCY has a market cap of $133.89 million. This is considered a Micro Cap stock.
Last quarter Unicycive Therapeutics reported $0 in Revenue and -$.46 earnings per share. This fell short of revenue expectation by $-265,620 and exceeded earnings estimates by $.09.
In the last 3 years, UNCY traded as high as $28.70 and as low as $2.02.
The top ETF exchange traded funds that UNCY belongs to (by Net Assets): VTI, VXF.
UNCY has underperformed the market in the last year with a return of -9.7%, while SPY returned +14.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in UNCY shares. However, UNCY has outperformed the market in the last 3 month and 2 week periods, returning +42.9% and +15.4%, while SPY returned +6.2% and +4.0%, respectively. This indicates UNCY has been having a stronger performance recently.
UNCY support price is $6.16 and resistance is $6.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UNCY shares will trade within this expected range on the day.
